Tech Company Financing Transactions

Euthymics Bioscience Funding Round

On 3/31/2012, Euthymics Bioscience raised $1.9 million in funding from GBS Venture Partners, Hambrecht & Quist Capital Management and Novartis Venture Fund.

Transaction Overview

Announced On
3/31/2012
Transaction Type
Venture Equity
Amount
$1,927,200
Round
Undisclosed
Investors
Proceeds Purpose
Proceeds purposes were not disclosed.

Company Information

Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
1 Bdwy. 14th Floor
Cambridge, MA 02142
USA
Email Address
Overview
Euthymics Bioscience, a neuroscience-focused biopharmaceutical company, develops medicines for central nervous system disorders.
Profile
Euthymics Bioscience LinkedIn Company Profile
Social Media
Euthymics Bioscience Company Twitter Account
Company News
Euthymics Bioscience News
Facebook
Euthymics Bioscience on Facebook
YouTube
Euthymics Bioscience on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
Anthony McKinney
  Anthony McKinney LinkedIn Profile  Anthony McKinney Twitter Account  Anthony McKinney News  Anthony McKinney on Facebook
Chief Marketing Officer
Katherine Laessig
  Katherine Laessig LinkedIn Profile  Katherine Laessig Twitter Account  Katherine Laessig News  Katherine Laessig on Facebook


 

 

Browse more venture capital transactions:

Prev: 3/31/2012: Coherex Medical venture capital transaction
Next: 3/31/2012: M86 Security venture capital transaction

 

Share this article

 


About Our Venture Capital Transactions Database

Our team works diligently to document funding rounds that are announced publicly. VC investment data records reported here are derived from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.

 


Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary